FDA official announcements and press releases

Twice-Yearly Lenacapavir Injection Shows 95% Effectiveness, 96% Risk Reduction in HIV Prevention

Dec 1, 2024, 01:35 PM

A twice-yearly injectable HIV prophylactic, Lenacapavir, has shown over 95% effectiveness in preventing HIV infections in men, according to recent studies. The injection has also been proven effective in women and offers a significant advantage over daily pills like F/TDF due to better adherence rates. Another study highlighted that a semi-annual injection reduced the risk of HIV infection by 96%. Additionally, achieving an undetectable viral load through consistent antiretroviral therapy means zero risk of transmission. This development represents a promising step toward combating HIV/AIDS, although questions remain about equitable access to the treatment.